News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Calistoga Pharmaceuticals' Delta-Isoform-Selective PI3 Kinase Inhibitor CAL-101 Recognized as One of Windhover Information Inc.'s ‘Top 10 Oncology Projects to Watch'


10/27/2010 11:12:02 AM

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that the company’s lead product candidate, CAL-101, an oral, delta-selective PI3K inhibitor, has been selected as one of the ‘Top 10 Oncology Projects to Watch’ by Windhover Information.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES